A carregar...
The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN
The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis share driver mutations that either activate the thrombopoietin receptor, MPL, or indirectly activate it through mutations in the gene for JAK2, its cognate tyrosine kinase. Paradoxically, although...
Na minha lista:
| Publicado no: | Front Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7987816/ https://ncbi.nlm.nih.gov/pubmed/33777803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.641613 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|